ArticleFrontiers in oncology2026
Deceptive initial presentation of systemic DLBCL with CNS progression following Oligometabolic PET/CT: case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present a diagnostically challenging case of a 51-year-old woman with systemic diffuse large B-cell lymphoma (DLBCL) that progressed to secondary central nervous system (CNS) involvement. The initial presentation was notable for a whole-body PET/CT scan showing only subtle, diffuse fluorodeoxyglucose uptake in lymph nodes and bone marrow (SUVmax <5.0), below conventional thresholds for malignancy. Four months later, the patient developed an acute encephalopathic illness accompanied by multiorgan dysfunction and a severe hyperinflammatory state consistent with hemophagocytic lymphohistiocytosis. Hallmark laboratory features included refractory lactic acidosis, extreme hyperferritinemia, markedly elevated lactate dehydrogenase, and profound CD4+ lymphopenia. Cranial imaging revealed rapidly progressive, non-specific parenchymal lesions. A definitive diagnosis of the non-germinal center B-cell (non-GCB) subtype of DLBCL was secured via biopsy of a readily accessible facial lymph node-rather than high-risk brain biopsy-illustrating a pivotal diagnostic principle. This case highlights that unexplained persistent lactic acidosis, extreme hyperferritinemia, and even subthreshold PET/CT findings can be sentinel signs of an underlying aggressive lymphoma. It emphasizes the need for high clinical suspicion and the pursuit of safe, extracranial biopsy sites to enable early diagnosis and intervention in such diagnostically elusive cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.